NO20092143L - Anvendelse av testosteron og en 5-HT1A-agonist ved behandling av seksuell dysfunksjon - Google Patents

Anvendelse av testosteron og en 5-HT1A-agonist ved behandling av seksuell dysfunksjon

Info

Publication number
NO20092143L
NO20092143L NO20092143A NO20092143A NO20092143L NO 20092143 L NO20092143 L NO 20092143L NO 20092143 A NO20092143 A NO 20092143A NO 20092143 A NO20092143 A NO 20092143A NO 20092143 L NO20092143 L NO 20092143L
Authority
NO
Norway
Prior art keywords
testosterone
sexual dysfunction
treatment
ht1a agonist
ht1a
Prior art date
Application number
NO20092143A
Other languages
English (en)
Other versions
NO343597B1 (no
Inventor
Jan Johan Adriaan Tuiten
Johannes Martinus Maria Bloemers
Robertus Petrus Johannes De Lange
Original Assignee
Emotional Brain Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emotional Brain Bv filed Critical Emotional Brain Bv
Publication of NO20092143L publication Critical patent/NO20092143L/no
Publication of NO343597B1 publication Critical patent/NO343597B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Abstract

Oppfinnelsen angår feltet av mannlig og/eller kvinnelig seksuell dysfunksjon. Oppfinnelsen angår spesifikt anvendelsen av testosteron og en 5-HT1A-agonist.
NO20092143A 2006-11-03 2009-06-03 Anvendelse av testosteron og en 5-HT1A-agonist ved behandling av seksuell dysfunksjon NO343597B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06076976A EP1925307A1 (en) 2006-11-03 2006-11-03 Use of 3-alpha-androstanediol in the treatment of sexual dysfunction
PCT/NL2007/050533 WO2008054213A2 (en) 2006-11-03 2007-11-02 Use of testosterone and a 5-ht1a agonist in the treatment of sexual dysfunction

Publications (2)

Publication Number Publication Date
NO20092143L true NO20092143L (no) 2009-07-02
NO343597B1 NO343597B1 (no) 2019-04-08

Family

ID=37846101

Family Applications (3)

Application Number Title Priority Date Filing Date
NO20092146A NO20092146L (no) 2006-11-03 2009-06-03 Anvendelse av 3-ALFA-Androstandiol, valgfritt i kombinasjon med en 5-HT1A-agonist, i behandlingen av seksuell dysfunksjon
NO20092143A NO343597B1 (no) 2006-11-03 2009-06-03 Anvendelse av testosteron og en 5-HT1A-agonist ved behandling av seksuell dysfunksjon
NO20092145A NO20092145L (no) 2006-11-03 2009-06-03 Anvendelse av 3-ALFA-Androstandiol, valgfritt i kombinasjon med en PDES-inhibitor, i behandlingen av seksuell dysfunksjon

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO20092146A NO20092146L (no) 2006-11-03 2009-06-03 Anvendelse av 3-ALFA-Androstandiol, valgfritt i kombinasjon med en 5-HT1A-agonist, i behandlingen av seksuell dysfunksjon

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20092145A NO20092145L (no) 2006-11-03 2009-06-03 Anvendelse av 3-ALFA-Androstandiol, valgfritt i kombinasjon med en PDES-inhibitor, i behandlingen av seksuell dysfunksjon

Country Status (28)

Country Link
US (10) US8575139B2 (no)
EP (5) EP1925307A1 (no)
JP (8) JP2010509212A (no)
KR (6) KR20090115113A (no)
CN (6) CN103381270A (no)
AU (3) AU2007314736B2 (no)
BR (3) BRPI0717963A2 (no)
CA (3) CA2668320C (no)
CY (1) CY1117191T1 (no)
DK (1) DK2086544T3 (no)
ES (1) ES2561946T3 (no)
HK (1) HK1135038A1 (no)
HR (1) HRP20160108T1 (no)
HU (1) HUE026752T2 (no)
IL (5) IL198461A (no)
ME (1) ME02410B (no)
MX (3) MX2009004695A (no)
NO (3) NO20092146L (no)
NZ (3) NZ577393A (no)
PH (2) PH12014501440A1 (no)
PL (1) PL2086544T3 (no)
PT (1) PT2086544E (no)
RS (1) RS54541B1 (no)
RU (4) RU2464027C2 (no)
SI (1) SI2086544T1 (no)
UA (4) UA101948C2 (no)
WO (3) WO2008054215A2 (no)
ZA (3) ZA200903837B (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1750766E (pt) 2004-05-11 2013-09-30 Emotional Brain Bv Formulações farmacêuticas e suas utilizações no tratamento de disfunção sexual feminina
EP1790343A1 (en) * 2005-11-11 2007-05-30 Emotional Brain B.V. Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction
EP1925307A1 (en) * 2006-11-03 2008-05-28 Emotional Brain B.V. Use of 3-alpha-androstanediol in the treatment of sexual dysfunction
EP2266568A1 (en) 2009-05-26 2010-12-29 Æterna Zentaris GmbH Use of LHRH antagonists in combination with PDE V inhibitors for the treatment of sex hormone dependent disorders
EP2266567A1 (en) 2009-05-26 2010-12-29 Æterna Zentaris GmbH Use of cetrorelix in combination with PDE V inhibitors for the treatment of sex hormone dependent disorders
CN109908099B (zh) * 2011-05-13 2021-10-29 Eb Ip希博里塔布斯有限责任公司 药物递送系统
HUE055562T2 (hu) 2011-11-23 2021-11-29 Therapeuticsmd Inc Természetes kombinációjú hormon helyettesítõ kiszerelések, és terápiák ezekkel
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
JP5828923B2 (ja) 2014-01-30 2015-12-09 国立大学法人高知大学 ニッケル粉の製造方法
JP5936783B2 (ja) 2014-02-21 2016-06-22 国立大学法人高知大学 ニッケル粉の製造方法
JP6406613B2 (ja) 2014-04-15 2018-10-17 住友金属鉱山株式会社 含有する炭素及び硫黄の濃度を低減するニッケル粉の製造方法
CN103947533B (zh) * 2014-05-15 2015-12-16 青岛理工大学 生长环境可控的磁化水工厂化豆芽菜生产系统
RU2600845C2 (ru) 2014-07-04 2016-10-27 Общество С Ограниченной Ответственностью "Консорциум-Пик" Применение производных оксатриазолий-5-олата для лечения сексуальных расстройств

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3251436A (en) * 1965-03-16 1966-05-17 Dayton Steel Foundry Co Spot-type disk brake
US3976776A (en) 1972-12-06 1976-08-24 Mead Johnson & Company Tranquilizer process employing N-(heteroarcyclic)piperazinylalkylazaspiroalkanediones
US4521421A (en) * 1983-09-26 1985-06-04 Eli Lilly And Company Treatment of sexual dysfunction
AU577802B2 (en) 1983-10-17 1988-10-06 Duphar International Research B.V. Blood-pressure lowering piperazine derivatives
US4596795A (en) 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
US4640921A (en) 1986-02-04 1987-02-03 Bristol-Myers Treatment of sexual dysfunction with buspirone
US5015646A (en) * 1987-08-28 1991-05-14 Bristol-Myers Squibb Co. Pharmaceutically useful polymorphic modification of buspirone
US4877774A (en) 1987-09-09 1989-10-31 The United States Of America As Represented By The Department Of Health And Human Services Administration of steroid hormones
CA1335106C (en) * 1989-02-27 1995-04-04 John Mehnert Schaus Ring-substituted 2-amino-1,2,3,4-tetra-hydronaphthalenes
US5447912A (en) 1989-09-18 1995-09-05 Senetek, Plc Erection-inducing methods and compositions
US5250534A (en) 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
US5431922A (en) * 1991-03-05 1995-07-11 Bristol-Myers Squibb Company Method for administration of buspirone
GB9301192D0 (en) * 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
US5565466A (en) 1993-08-13 1996-10-15 Zonagen, Inc. Methods for modulating the human sexual response
RU2152787C2 (ru) * 1994-06-02 2000-07-20 Дан Рига Лекарство против стресса, против снижения уровня активности и против старения и способ его получения
BR9408581A (pt) 1994-06-02 1997-08-26 Dan Riga Medicamento anti-tens o anti-incapacitação e anti-envelhecimento e processo para a sua produção
US5698560A (en) 1995-03-01 1997-12-16 Kyowa Hakko Kogyo Co., Ltd. Imidazoquinazoline derivatives
WO1996028142A1 (en) 1995-03-14 1996-09-19 Vivus, Incorporated Method and kit for preventing erectile dysfunction
US5731339A (en) 1995-04-28 1998-03-24 Zonagen, Inc. Methods and formulations for modulating the human sexual response
CA2219082A1 (en) 1995-05-15 1996-11-21 Beth Israel Deaconess Medical Center, Inc. Use of dihydrotestosterone compounds for treating male sexual dysfunction
GB9514464D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
US6251436B1 (en) 1995-09-29 2001-06-26 L.A.M. Pharmaceutical Corporation Drug preparations for treating sexual dysfunction
US6242198B1 (en) 1996-07-25 2001-06-05 Cambridge Neuroscience, Inc. Methods of treatment of eye trauma and disorders
DE69833254T2 (de) 1997-06-23 2006-11-02 Cellegy Pharmaceuticals, Inc., Brisbane Microdosistherapie von gefässbedingten erscheinungen durch no-donoren
CA2306837C (en) * 1997-10-28 2007-05-08 Asivi, Llc. Treatment of female sexual dysfunction
US20040014761A1 (en) 1997-10-28 2004-01-22 Place Virgil A. Treatment of female sexual dysfunction with phosphodiesterase inhibitors
US20020013304A1 (en) 1997-10-28 2002-01-31 Wilson Leland F. As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness
US5877216A (en) 1997-10-28 1999-03-02 Vivus, Incorporated Treatment of female sexual dysfunction
US6246436B1 (en) 1997-11-03 2001-06-12 Agilent Technologies, Inc Adjustable gain active pixel sensor
TW542719B (en) 1998-02-23 2003-07-21 Pfizer Res & Dev Method of treating impotence due to spinal cord injury
US6403605B1 (en) 1998-05-29 2002-06-11 Queen's University At Kingston Methods for the normalization of sexual response and amelioration of long term genital tissue degradation
UA67802C2 (uk) * 1998-10-23 2004-07-15 Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції
US6613768B1 (en) 1999-04-30 2003-09-02 Lilly Icos Llc Treatment of female arousal disorder
US6632419B2 (en) 1999-05-04 2003-10-14 Aradigm Corporation Increasing libido in humans via acute testosterone administration
US6428769B1 (en) 1999-05-04 2002-08-06 Aradigm Corporation Acute testosterone administration
US7258850B2 (en) 1999-05-04 2007-08-21 Aradigm Corporation Methods and compositions for treating erectile dysfunction
CA2377339A1 (en) 1999-06-17 2000-12-28 Armin Johannes Becker Administration of growth hormone (hgh) for the therapy of sexual functional disorders
RU2180591C2 (ru) 1999-12-24 2002-03-20 Государственное научное предприятие Московский научно-исследовательский институт психиатрии МЗ РФ Средство для лечения сексуальных дисфункций у мужчин
DE10016548A1 (de) 2000-04-03 2001-10-11 Bayer Ag Polyurethan-Dispersionen
US6313172B1 (en) 2000-04-13 2001-11-06 Allergan Sales, Inc. Methods and compositions for modulating alpha adrenergic receptor activity
US6242436B1 (en) * 2000-06-15 2001-06-05 William Charles Llewellyn Use of 5alpha-androstanediol or 5alpha-androstanedione to increase dihydrotestosterone levels in humans
US7198801B2 (en) 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
US20040092494A9 (en) 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
ATE460939T1 (de) 2000-08-30 2010-04-15 Unimed Pharmaceuticals Llc Verfahren zur behandlung von erektionsstörungen und steigerung der libido bei männern
US20030139384A1 (en) 2000-08-30 2003-07-24 Dudley Robert E. Method for treating erectile dysfunction and increasing libido in men
SK287066B6 (sk) 2000-09-29 2009-11-05 Solvay Pharmaceuticals B. V. Farmaceutická formulácia s predĺženým uvoľňovaním a spôsob jej prípravy
US20060287335A1 (en) 2000-11-28 2006-12-21 Wyeth Serotonergic agents for treating sexual dysfunction
NZ526925A (en) * 2000-12-15 2005-03-24 Pfizer Treatment of male sexual dysfunction
US20020107230A1 (en) 2000-12-22 2002-08-08 Waldon R. Forrest Methods and formulations for the treatment of female sexual dysfunction
WO2002069906A2 (en) 2001-03-06 2002-09-12 Cellegy Pharmaceuticals, Inc. Compounds and methods for the treatment of urogenital disorders
EA006154B1 (ru) 2001-03-28 2005-10-27 Пфайзер Инк. N-фенпропилциклопентил-замещенные производные глутарамида в качестве nep ингибиторов при fsad
EP1260225A1 (en) * 2001-05-18 2002-11-27 Pantarhei Bioscience B.V. A pharmaceutical composition for use in hormone replacement therapy
US20030027804A1 (en) 2001-06-27 2003-02-06 Van Der Hoop Roland Gerritsen Therapeutic combinations for the treatment of hormone deficiencies
US20030022875A1 (en) 2001-07-27 2003-01-30 Wilson Leland F. As-needed administration of orally active androgenic agents to enhance female sexual desire and responsiveness
UA78974C2 (en) * 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US20040259852A1 (en) 2003-06-18 2004-12-23 White Hillary D. Trandsdermal compositions and methods for treatment of fibromyalgia and chronic fatigue syndrome
EP1653966A1 (en) * 2003-07-16 2006-05-10 Pfizer Limited Treatment of sexual dysfunction
US20050065158A1 (en) * 2003-07-16 2005-03-24 Pfizer Inc. Treatment of sexual dysfunction
ATE319426T1 (de) 2003-11-11 2006-03-15 Mattern Udo Nasenformulierung mit kontrollierter freisetzung von sexualhormonen
WO2005094827A1 (en) * 2004-03-30 2005-10-13 Kestrel Pharmaceuticals Inc. Methods for treating sexual dysfunction
KR20070014184A (ko) 2004-04-22 2007-01-31 베링거 인겔하임 인터내셔날 게엠베하 성기능 장애 치료용 신규 약제학적 조성물 ⅱ
PT1750766E (pt) * 2004-05-11 2013-09-30 Emotional Brain Bv Formulações farmacêuticas e suas utilizações no tratamento de disfunção sexual feminina
KR20080016552A (ko) * 2005-04-13 2008-02-21 유니메드 파마슈티칼스, 인크. 여성의 테스토스테론 및 관련된 스테로이드의 농도를증가시키는 방법
WO2006127057A1 (en) 2005-05-24 2006-11-30 Lyle Corporate Drvelopment, Inc. Non-systematic vaginal administration of estrogen and an androgen for the treatment of sexual dysfunction
WO2006125642A1 (en) 2005-05-27 2006-11-30 Antares Pharma Ipl Ag Methods and apparatus for transdermal or transmucosal application of testosterone
WO2007054791A2 (en) 2005-11-08 2007-05-18 L'oréal Androgen glucuronides as markers of androgenic activity
EP1790343A1 (en) 2005-11-11 2007-05-30 Emotional Brain B.V. Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction
EP1925307A1 (en) 2006-11-03 2008-05-28 Emotional Brain B.V. Use of 3-alpha-androstanediol in the treatment of sexual dysfunction
US8592477B2 (en) 2007-11-28 2013-11-26 Ucb Pharma Gmbh Polymorphic form of rotigotine and process for production

Also Published As

Publication number Publication date
ZA200903835B (en) 2010-10-27
PL2086544T3 (pl) 2016-07-29
HK1135038A1 (en) 2010-05-28
EP2086544A2 (en) 2009-08-12
RU2012125827A (ru) 2013-12-27
JP2015157849A (ja) 2015-09-03
PH12014501821B1 (en) 2016-02-01
WO2008054213A3 (en) 2009-04-09
US20100093680A1 (en) 2010-04-15
IL198459A (en) 2016-11-30
ES2561946T3 (es) 2016-03-01
JP2014111608A (ja) 2014-06-19
US8653051B2 (en) 2014-02-18
CN101563086B (zh) 2013-11-27
AU2007314735A1 (en) 2008-05-08
US8575139B2 (en) 2013-11-05
AU2007314734B2 (en) 2014-01-30
IL248563A0 (en) 2016-12-29
JP6357131B2 (ja) 2018-07-11
IL198459A0 (en) 2010-02-17
ME02410B (me) 2016-09-20
KR20090115113A (ko) 2009-11-04
SI2086544T1 (sl) 2016-04-29
IL198460A (en) 2016-11-30
NO20092146L (no) 2009-07-21
CN103381270A (zh) 2013-11-06
BRPI0717856A2 (pt) 2013-10-29
KR20090111802A (ko) 2009-10-27
JP2010509213A (ja) 2010-03-25
CN104524580A (zh) 2015-04-22
CA2668320A1 (en) 2008-05-08
CN101563086A (zh) 2009-10-21
AU2007314734A1 (en) 2008-05-08
US20100160270A1 (en) 2010-06-24
WO2008054215A2 (en) 2008-05-08
PT2086544E (pt) 2016-03-17
IL237786A0 (en) 2015-05-31
US20160082018A1 (en) 2016-03-24
US8648060B2 (en) 2014-02-11
DK2086544T3 (en) 2016-02-08
EP1925307A1 (en) 2008-05-28
UA115647C2 (uk) 2017-12-11
EP2086545A2 (en) 2009-08-12
CA2668316A1 (en) 2008-05-08
EP2086544B1 (en) 2015-12-23
JP2010509212A (ja) 2010-03-25
US20140121190A1 (en) 2014-05-01
BRPI0717963A2 (pt) 2013-11-05
US9597335B2 (en) 2017-03-21
CA2668316C (en) 2014-06-10
KR20090111803A (ko) 2009-10-27
US20100152145A1 (en) 2010-06-17
CA2668320C (en) 2014-06-10
KR20150099620A (ko) 2015-08-31
US10314848B2 (en) 2019-06-11
US20170157142A1 (en) 2017-06-08
NZ577393A (en) 2012-11-30
BRPI0718396A2 (pt) 2013-11-26
UA103592C2 (uk) 2013-11-11
CN103599536A (zh) 2014-02-26
RU2491073C2 (ru) 2013-08-27
ZA200903837B (en) 2010-08-25
IL248563B (en) 2018-11-29
WO2008054214A3 (en) 2009-04-09
MX2009004695A (es) 2009-06-05
US20190262359A1 (en) 2019-08-29
RU2009120990A (ru) 2010-12-10
NO20092145L (no) 2009-07-21
AU2007314736A1 (en) 2008-05-08
US9211334B2 (en) 2015-12-15
KR20160124246A (ko) 2016-10-26
JP2010509211A (ja) 2010-03-25
WO2008054214A2 (en) 2008-05-08
IL198460A0 (en) 2010-02-17
US20140038929A1 (en) 2014-02-06
CA2668317A1 (en) 2008-05-08
RS54541B1 (en) 2016-06-30
CN101557812A (zh) 2009-10-14
JP2014055142A (ja) 2014-03-27
CA2668317C (en) 2016-02-09
CY1117191T1 (el) 2017-04-05
MX2009004696A (es) 2009-06-05
NZ577390A (en) 2012-12-21
KR20150038251A (ko) 2015-04-08
AU2007314735B2 (en) 2014-01-16
PH12014501440A1 (en) 2016-02-01
RU2009120988A (ru) 2010-12-10
EP2937086A1 (en) 2015-10-28
RU2464027C2 (ru) 2012-10-20
US8669242B2 (en) 2014-03-11
PH12014501821A1 (en) 2016-02-01
WO2008054213A2 (en) 2008-05-08
WO2008054215A3 (en) 2009-04-09
UA100119C2 (uk) 2012-11-26
JP2017132809A (ja) 2017-08-03
EP2086548A2 (en) 2009-08-12
RU2463054C2 (ru) 2012-10-10
MX2009004693A (es) 2009-06-05
KR101796887B1 (ko) 2017-11-10
ZA200903836B (en) 2010-08-25
NZ577392A (en) 2012-11-30
IL198461A0 (en) 2010-02-17
JP5748238B2 (ja) 2015-07-15
NO343597B1 (no) 2019-04-08
HRP20160108T1 (hr) 2016-03-25
IL198461A (en) 2017-08-31
RU2646447C2 (ru) 2018-03-05
US20120277200A1 (en) 2012-11-01
RU2009120992A (ru) 2010-12-10
UA101948C2 (uk) 2013-05-27
JP2014001235A (ja) 2014-01-09
KR101578224B1 (ko) 2015-12-16
US20140121189A1 (en) 2014-05-01
HUE026752T2 (en) 2016-07-28
CN101573119A (zh) 2009-11-04
AU2007314736B2 (en) 2014-01-23

Similar Documents

Publication Publication Date Title
NO20092143L (no) Anvendelse av testosteron og en 5-HT1A-agonist ved behandling av seksuell dysfunksjon
MX360301B (es) Moleculas pequeñas que contienen boro como agentes antiinflamatorios.
AU308855S (en) Camera
GB0515353D0 (en) Food
MY160041A (en) Compositions and methods for treating parasitic infections
CA127556S (en) Massager male
MX2010007490A (es) Preparacion de derivados de sulfamida.
EP2069377A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF SKIN DISEASES AND SKIN FUNCTIONAL DISORDERS
IL191280A (en) Medical combinations containing testosterone for the treatment of sexual dysfunction in women
IT1395957B1 (it) Uso di una combinazione di d-aspartato e l-aspartato per il trattamento della infertilita' maschile.
CA122665S (en) Trigger latch
CA117272S (en) Cake server
CA118787S (en) Handle
EP2305273A4 (en) USE OF ICARISIDE II IN THE MANUFACTURE OF PRODUCTS TO PREVENT OR TREAT MALE OR FEMALE SEXUAL DYSFUNCTION
CA124277S (en) Necklace
CA120494S (en) Sling shot
AU311277S (en) Hammer
CA129499S (en) Massager
UA29769U (ru) Применение мигрепина как вещества с противовоспалительными и жаропонижающими свойствами
CA120869S (en) Artificial stone wall
CA120870S (en) Artificial stone wall
CA120868S (en) Artificial stone wall
AU316136S (en) 'Wafer baker' 4 hole star shape
UA39463U (ru) Способ лечения больных артериальной гипертензией и избыточной массой тела
AU301369S (en) Tube

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: EB IP LYBRIDOS B.V., NL

MM1K Lapsed by not paying the annual fees